Biden Could Share Vaccine Data With The World

Link: https://www.dailyposter.com/biden-could-share-vaccine-data-with-the-world/

Excerpt:

Wealthy, vaccine manufacturing countries like Germany, France, and the U.S. have pledged to fully vaccinate their own populations while also sharing doses with the developing world. But it’s not clear that a sufficient number of doses currently exist for them to make good on this promise. The European Union, for example, is on track to fall far short of its goal of donating 200 million doses to non-member states by the end of the year. And as of August, COVAX, the World Health Organization’s (WHO) vaccine sharing initiative, had distributed 188 million vaccines worldwide, just 19 percent of the 1.1 billion that the WHO says are needed to end the pandemic.

The more people remain unvaccinated worldwide, the likelier it is that new variants will emerge, endangering vaccinated and unvaccinated alike.

The Biden administration’s strategy for expanding worldwide vaccine access has largely relied on pushing for vaccine patent waivers through negotiations at the World Trade Organization. But those negotiations have been stymied by strong opposition from member states of the European Union, meaning that unilateral American action may be necessary to expand vaccine access on the necessary scale.

Legally, the U.S. may already have the ability to do so. The terms between Moderna and the federal government specify that the government possesses rights to the vaccine technology developed under the contract, meaning that it can unilaterally publish or share the data with anyone. Furthermore, an essential component of the Moderna vaccine was invented and patented by U.S. government researchers, meaning that the government could threaten a patent infringement suit against Moderna if the company refuses to share its vaccine know-how.

Author(s): Sam Mellins

Publication Date: 7 September 2021

Publication Site: The Daily Poster

Comparing the COVID-19 Vaccines: How Are They Different?

Link: https://www.yalemedicine.org/news/covid-19-vaccine-comparison

Excerpt:

In the United States, the number of cases and deaths that had been rising to a peak for almost a year have been flattening out, thanks, in large part, to COVID-19 vaccinations that began in December. As the weeks pass, more reports have been coming out about the effectiveness of the vaccines that are in use and the potential of those still in development. So, how do they differ? 

It’s important to keep up, but it’s also a daunting task, given the flood of information (and misinformation) coming at us from so many directions.

Vaccines from Pfizer-BioNTech, Moderna, and Johnson & Johnson are being administered in the U.S. right now, and others are on track to do the same. 

We mapped out a comparison of the most prominent COVID-19 vaccines.

Author(s): Kathy Katella

Publication Date: 1 July 2021 (originally published February 2021, updated)

Publication Site: Yale Medicine

CDC says vaccine link to heart inflammation is stronger than previously thought

Link: https://thehill.com/changing-america/well-being/prevention-cures/558321-cdc-says-vaccine-link-to-heart-inflammation-is

Excerpt:

Males under 30 may face heart problems after getting vaccinated.

Myocarditis and pericarditis share the same symptoms.

Treatment for myocarditis can be solved with over-the-counter medication or resolve itself.

Author(s): Christian Spencer

Publication Date: 14 June 2021

Publication Site: The Hill

Covid vaccine: How many people in the UK have been vaccinated so far?

Link: https://www.bbc.com/news/health-55274833

Graphic:

Excerpt:

The UK has four vaccines approved for use: Pfizer-BioNTech, Oxford-AstraZeneca, Moderna and Janssen; three of which require two doses for maximum protection.

The campaign to reach as many people as quickly as possible was boosted by a shift in policy in early January – to prioritise the first dose of a vaccine, with a second dose up to 12 weeks later, a bigger gap than originally planned.

Progress made in the UK so far means the country continues to be among those with the highest vaccination rates globally.

Author(s): The Visual and Data Journalism Team

Publication Date: 15 June 2021

Publication Site: BBC

Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases and a comparison with 489,871 people receiving a COVID-19 mRNA vaccine

Link: https://osf.io/a9jdq/

Graphic:

Abstract:

Using an electronic health records network we estimated the absolute incidence of cerebral venous thrombosis (CVT) in the two weeks following COVID-19 diagnosis(N=513,284), or influenza (N=172,742), or receipt of the BNT162b2 or mRNA-1273 COVID-19 vaccines(N=489,871). The incidence of portal vein thrombosis (PVT) was also assessed in these groups, as well as the baselineCVTincidence over a two-week period. The incidence of CVT after COVID-19 diagnosis was 39.0 per million people (95% CI, 25.2–60.2). This was higher than the CVT incidence after influenza (0.0 per million people, 95% CI 0.0–22.2, adjusted RR=6.73, P=.003) or after receiving BNT162b2 or mRNA-1273 vaccine (4.1 per million people, 95% CI 1.1–14.9, adjusted RR=6.36, P<.001). The relative risks were similar if a broader definition of CVT was used. For PVT, the incidence was 436.4 per million people (382.9-497.4) after COVID-19, 98.4 (61.4-157.6) after influenza, and 44.9 (29.7-68.0) after BNT162b2 or mRNA-1273. The incidence of CVT following COVID-19 was higher than the incidence observed across the entire health records network (0.41 per million people over any 2-week period). Laboratory test results, available in a subset of the COVID-19 patients, provide preliminary evidence suggestive of raised D-dimer, lowered fibrinogen, and an increased rate of thrombocytopenia in the CVT and PVT groups. Mortality was 20% and 18.8% respectively. These data show that the incidence of CVT is significantly increased after COVID-19, and greater than that observed with BNT162b2 and mRNA-1273 COVID-19 vaccines. The risk of CVT following COVID-19 is also higher than the latest estimate from the European Medicines Agency for the incidence associated withChAdOx1 nCoV-19 vaccine (5.0 per million people, 95% CI 4.3–5.8). Although requiring replication and corroboration, the present data highlight the risk of serious thrombotic events in COVID-19, and can help contextualize the risks and benefits of vaccination in this regard.

Author(s): Maxime Taquet, Masud Husain, John R Geddes, Sierra Luciano, Paul J Harrison

Date Accessed: 19 April 2021

Publication Site: OSFHOME

Blood clots as prevalent with Pfizer and Moderna vaccine as with AstraZeneca’s: study

Link: https://www.marketwatch.com/story/blood-clots-as-prevalent-with-pfizer-and-moderna-vaccine-as-with-astrazenecas-report-2021-04-15

Excerpt:

study by Oxford University found the number of people who receive blood clots after getting vaccinated with a coronavirus vaccine are about the same for those who get Pfizer PFE, 2.43% and Moderna MRNA, 6.67% vaccines as they are for the AstraZeneca AZN, -0.16% vaccine that was produced with the university’s help. According to the study, 4 in 1 million people experience cerebral venous thrombosis after getting the Pfizer or Moderna vaccine, versus 5 in 1 million people for the AstraZeneca vaccine. The risk of getting CVT is much higher for those who get COVID-19 — 39 in a million patients — than it is for those who get vaccinated. AstraZeneca’s vaccine use has been halted or limited in many countries on blood clot concerns.

Author(s): Steve Goldstein

Publication Date: 15 April 2021

Publication Site: Marketwatch

Moderna Is Testing Its Covid-19 Vaccine on Young Children

Link: https://www.wsj.com/articles/moderna-is-testing-its-covid-19-vaccine-on-young-children-11615892416

Excerpt:

Moderna Inc. has begun studying its Covid-19 vaccine in children aged 6 months to 11 years in the U.S. and Canada, the latest effort to widen the mass-vaccination campaign beyond adults.

The Cambridge, Mass., company said Tuesday that the first children have received doses in the study, which Moderna is conducting in collaboration with the National Institute of Allergy and Infectious Diseases and a division of the Department of Health and Human Services.

“This pediatric study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population,” Moderna Chief Executive Stéphane Bancel said.

Author(s): Peter Loftus

Publication Date: 16 March 2021

Publication Site: Wall Street Journal

Dolly Parton gets first dose of COVID-19 vaccine she helped fund

Link: https://abc11.com/10383614/

Excerpt:

Dolly Parton has received her first shot of the Moderna COVID-19 vaccine she helped fund with a $1 million donation to Vanderbilt University last year.

Parton chronicled the vaccination process in a video posted Tuesday to social media. In it, she sang a parody of her hit song “Jolene” with new lyrics imploring people to get vaccinated.

“Vaccine, vaccine, vaccine, vaccine,” she sang in the famous tune. “I’m begging of you please don’t hesitate.”

Publication Date: 2 March 2021

Publication Site: ABC 11 Eyewitness News

Moderna Says Covid-19 Vaccine for South Africa Strain Is Ready for Human Testing

Link: https://www.wsj.com/articles/moderna-says-covid-19-vaccine-for-south-africa-strain-is-ready-for-human-testing-11614201000

Excerpt:

Moderna Inc. said it has made the initial batch of doses of a new Covid-19 vaccine designed to better protect people against a new strain of the coronavirus that has shown some resistance to the company’s original vaccine.

The Cambridge, Mass., company on Wednesday said it shipped the new shots to the National Institutes of Health to conduct the first human study of the variant vaccine, which could start within weeks.

The new vaccine, code-named mRNA-1273.351, is designed to better match the virus variant that was first identified in South Africa but has since spread elsewhere.

Moderna, which makes the second Covid-19 shot authorized in the U.S., might be the first vaccine maker to have finished the laboratory work of designing a shot targeting variants that started spreading swiftly late last year.

Author(s): Peter Loftus

Publication Date: 24 February 2021

Publication Site: Wall Street Journal